Latest BML Capital Management, LLC Stock Portfolio
BML Capital Management, LLC Performance:
2025 Q2: 8.01%YTD: -13%2024: 6.29%
Performance for 2025 Q2 is 8.01%, and YTD is -13%, and 2024 is 6.29%.
About BML Capital Management, LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, BML Capital Management, LLC reported an equity portfolio of $132.2 Millions as of 30 Jun, 2025.
The top stock holdings of BML Capital Management, LLC are AVIR, THRD, ACRS. The fund has invested 20.7% of it's portfolio in ATEA PHARMACEUTICALS INC and 15.7% of portfolio in THIRD HARMONIC BIO INC.
The fund managers got completely rid off AN2 THERAPEUTICS INC (ANTX), WHITEHAWK THERAPEUTICS INC (AADI) and SAGE THERAPEUTICS INC (SAGE) stocks. They significantly reduced their stock positions in CONNECT BIOPHARMA HLDGS LTD (CNTB), LISATA THERAPEUTICS INC (CLBS) and ELEVATION ONCOLOGY INC (ELEV). BML Capital Management, LLC opened new stock positions in CORVUS PHARMACEUTICALS INC (CRVS). The fund showed a lot of confidence in some stocks as they added substantially to ALUMIS INC, HILLEVAX INC (HLVX) and KEZAR LIFE SCIENCES INC (KZR).
The top stock holdings of BML Capital Management, LLC are AVIR, THRD, ACRS. The fund has invested 20.7% of it's portfolio in ATEA PHARMACEUTICALS INC and 15.7% of portfolio in THIRD HARMONIC BIO INC.
The fund managers got completely rid off AN2 THERAPEUTICS INC (ANTX), WHITEHAWK THERAPEUTICS INC (AADI) and SAGE THERAPEUTICS INC (SAGE) stocks. They significantly reduced their stock positions in CONNECT BIOPHARMA HLDGS LTD (CNTB), LISATA THERAPEUTICS INC (CLBS) and ELEVATION ONCOLOGY INC (ELEV). BML Capital Management, LLC opened new stock positions in CORVUS PHARMACEUTICALS INC (CRVS). The fund showed a lot of confidence in some stocks as they added substantially to ALUMIS INC, HILLEVAX INC (HLVX) and KEZAR LIFE SCIENCES INC (KZR).
BML Capital Management, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that BML Capital Management, LLC made a return of 8.01% in the last quarter. In trailing 12 months, it's portfolio return was -1.37%.
New Buys
| Ticker | $ Bought |
|---|---|
| corvus pharmaceuticals inc | 475,064 |
New stocks bought by BML Capital Management, LLC
Additions
| Ticker | % Inc. |
|---|---|
| alumis inc | 2,339 |
| hillevax inc | 342 |
| kezar life sciences inc | 55.63 |
| pmv pharmaceuticals inc | 33.42 |
| instil bio inc | 28.36 |
| adverum biotechnologies inc | 11.49 |
| ikena oncology inc | 8.6 |
| oramed pharmaceuticals inc | 2.07 |
Additions to existing portfolio by BML Capital Management, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| connect biopharma hldgs ltd | -12.98 |
| lisata therapeutics inc | -3.25 |
| elevation oncology inc | -0.01 |
BML Capital Management, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| an2 therapeutics inc | -7,819,230 |
| achilles therapeutics plc | 0.00 |
| whitehawk therapeutics inc | -3,364,640 |
| sage therapeutics inc | -1,074,000 |
| nextcure inc | -131,379 |
BML Capital Management, LLC got rid off the above stocks
Sector Distribution
BML Capital Management, LLC has about 91.9% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 91.9 |
| Others | 6.7 |
Market Cap. Distribution
BML Capital Management, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MICRO-CAP | 73.7 |
| SMALL-CAP | 15.9 |
| UNALLOCATED | 6.7 |
| NANO-CAP | 3.7 |
Stocks belong to which Index?
About 63% of the stocks held by BML Capital Management, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 63 |
| Others | 37 |
BML Capital Management, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of BML Capital Management, LLC
BML Capital Management, LLC has 23 stocks in it's portfolio. About 86.7% of the portfolio is in top 10 stocks. ADVM proved to be the most loss making stock for the portfolio. THRD was the most profitable stock for BML Capital Management, LLC last quarter.
Last Reported on: 11 Aug, 2025| Ticker | Namesorted descending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AVIR | atea pharmaceuticals inc | 20.73 | 7,609,810 | 27,395,300 | unchanged | 0.00 | ||
Historical Trend of ATEA PHARMACEUTICALS INC Position Held By BML Capital Management, LLCWhat % of Portfolio is AVIR?:Number of AVIR shares held:Change in No. of Shares Held: | ||||||||
| THRD | third harmonic bio inc | 15.71 | 3,824,420 | 20,766,600 | unchanged | 0.00 | ||
| ACRS | aclaris therapeutics inc | 15.31 | 14,250,000 | 20,235,000 | unchanged | 0.00 | ||
| TIL | instil bio inc | 8.43 | 534,899 | 11,141,900 | added | 28.36 | ||
| EPIX | essa pharma inc | 5.43 | 4,221,550 | 7,176,630 | unchanged | 0.00 | ||
| ORMP | oramed pharmaceuticals inc | 5.25 | 3,083,250 | 6,937,320 | added | 2.07 | ||
| ADVM | adverum biotechnologies inc | 4.97 | 3,057,530 | 6,573,680 | added | 11.49 | ||
| IKNA | ikena oncology inc | 4.09 | 335,842 | 5,400,340 | added | 8.6 | ||
| PMVP | pmv pharmaceuticals inc | 4.01 | 5,000,000 | 5,300,000 | added | 33.42 | ||
| alumis inc | 2.75 | 1,210,420 | 3,631,240 | added | 2,339 | |||
| KZR | kezar life sciences inc | 2.20 | 635,183 | 2,909,140 | added | 55.63 | ||
| lava therapeutics nv | 1.97 | 1,970,610 | 2,601,200 | added | 0.51 | |||
| MIST | milestone pharmaceuticals in | 1.67 | 1,136,090 | 2,204,020 | unchanged | 0.00 | ||
| ELEV | elevation oncology inc | 1.64 | 5,890,430 | 2,162,380 | reduced | -0.01 | ||
| CNTB | connect biopharma hldgs ltd | 1.35 | 1,821,560 | 1,785,130 | reduced | -12.98 | ||
| ASTC | astrotech corp | 0.96 | 220,410 | 1,272,870 | unchanged | 0.00 | ||
| ATHA | athira pharma inc | 0.74 | 3,230,670 | 975,661 | added | 0.94 | ||
| CLBS | lisata therapeutics inc | 0.46 | 209,814 | 608,272 | reduced | -3.25 | ||
| CRVS | corvus pharmaceuticals inc | 0.36 | 118,766 | 475,064 | new | |||
| turnstone biologics corp | 0.30 | 1,103,390 | 396,116 | unchanged | 0.00 | |||
